Cereno Scientific – executive interview

Cereno Scientific (OMX: CRNO-B) is a clinical-stage biotech focused on developing treatments for cardiovascular diseases (CVD) using novel approaches. The company has an exciting pipeline of differentiated assets targeting unmet needs in CVD, with two clinical programmes and one preclinical programme. Lead candidate CS1 has an interesting mechanism of action (a histone deacetylase inhibitor (HDACi) showing epigenetic modulation properties) and promises disease-modifying properties in pulmonary arterial hypertension (PAH), a rare, debilitating and progressive condition with no curative therapies. The company recently presented positive Phase IIa data for CS1 and is gearing up for discussions with regulators on a potential Phase IIB/III pivotal study. The potential of Cereno’s HDACi programme to reverse disease progression in PAH was also highlighted in the preclinical data reported recently for CS014, the company’s other HDACi programme, which entered the clinic in June 2024 and is in a Phase I trial for thrombosis prevention (the leading cause of morbidity in CVD), but without the increased risk of bleeding associated with currently available antithrombotics. The preclinical asset CS585, a novel prostacyclin (IP) receptor agonist, is currently under evaluation for different CVD indications, backed by encouraging preclinical data.

In this video, we talk to Sten Sörensen, CEO of Cereno Scientific, about the exciting clinical data for CS1 and what the results mean for the company’s near-term development plans. We also discuss Cereno’s other pipeline assets as well as key upcoming catalysts.